The Role of Central Serotonergic and Adrenergic Systems in the Effectiveness of DNIC (Diffuse Noxious Inhibitory Control

The recruitment status of this study is unknown because the information has not been verified recently.
Verified February 2008 by Rambam Health Care Campus.
Recruitment status was  Active, not recruiting
Sponsor:
Information provided by:
Rambam Health Care Campus
ClinicalTrials.gov Identifier:
NCT00660751
First received: April 15, 2008
Last updated: April 16, 2008
Last verified: February 2008
  Purpose

The role of central serotonergic and adrenergic systems in the effectiveness of DNIC (Diffuse Noxious Inhibitory Control) will be tested before and after taking Duloxetine and Placebo in a double blind study.


Condition Intervention
Healthy
Drug: Duloxetine

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Single Group Assignment
Masking: Double Blind (Subject, Investigator, Outcomes Assessor)
Primary Purpose: Basic Science
Official Title: The Role of Central Serotonergic and Adrenergic Systems in the Effectiveness of DNIC (Diffuse Noxious Inhibitory Control

Resource links provided by NLM:


Further study details as provided by Rambam Health Care Campus:

Primary Outcome Measures:
  • level of DNIC [ Time Frame: 1 week ] [ Designated as safety issue: No ]

Estimated Enrollment: 100
Study Start Date: August 2007
Estimated Primary Completion Date: August 2009 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Active Comparator: 1 Drug: Duloxetine
SNRIs
Placebo Comparator: 2 Drug: Duloxetine
SNRIs

  Eligibility

Ages Eligible for Study:   18 Years to 80 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • Healthy volunteers
  • age 18-80
  • no chronic disease

Exclusion Criteria:

  • Subjects who suffer from chronic pain / pain syndrome
  • use of anti-depressant or anti-psychotic drugs
  • food/ drugs sensitivity
  • breast feeding
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00660751

Locations
Israel
Rambam Health Care Campus
Haifa, Israel, 31096
Sponsors and Collaborators
Rambam Health Care Campus
Investigators
Principal Investigator: Prof. David Yarnitsky
  More Information

No publications provided

Responsible Party: Prof. David Yarnitsky/ Head of Neurology Department, Rambam Health Care Campus
ClinicalTrials.gov Identifier: NCT00660751     History of Changes
Other Study ID Numbers: DNIC01CTIL
Study First Received: April 15, 2008
Last Updated: April 16, 2008
Health Authority: Israel: Ministry of Health

Keywords provided by Rambam Health Care Campus:
Physiology of Serotonergic and Adrenergic systems

Additional relevant MeSH terms:
Adrenergic Agents
Molecular Mechanisms of Pharmacological Action
Neurotransmitter Agents
Pharmacologic Actions
Physiological Effects of Drugs

ClinicalTrials.gov processed this record on October 21, 2014